📊 AORT Key Takeaways
Is Artivion, Inc.. (AORT) a Good Investment?
Artivion demonstrates strong revenue growth and excellent gross margins, but is operationally unprofitable with negative free cash flow (-$6.8M) and critically weak interest coverage (0.2x), indicating inability to service debt from operations. The severe disconnect between 64.9% gross margins and 1.2% net margins reflects significant operating inefficiencies that are not improving despite 13.6% revenue growth.
Artivion shows solid top-line momentum and strong gross profitability, indicating healthy demand and product economics. However, that growth is not yet translating into strong bottom-line or cash-flow performance, with thin net margins, weak returns on capital, minimal free cash flow, and limited interest coverage constraining financial flexibility. The fundamentals support a neutral view until operating leverage and cash conversion improve more clearly.
Artivion, Inc.. Key Strengths (AORT)
- Strong gross margins of 64.9% indicate product value and pricing power
- Revenue growth of 13.6% YoY shows market demand in medical device sector
- Solid short-term liquidity with current ratio of 3.86x and quick ratio of 2.80x
- Revenue growth of 13.6% YoY indicates strong commercial momentum
- Gross margin of 64.4% suggests attractive product mix and pricing power
- Liquidity is solid, with a 3.53x current ratio and manageable debt/equity of 0.48x
AORT Stock Risks: Artivion, Inc.. Investment Risks
- Negative free cash flow of -$6.8M indicates company is burning cash despite top-line growth
- Interest coverage ratio of 0.2x is critically low - operating income insufficient to cover debt service
- Net profitability severely compressed (1.2% margin) with minimal ROE (0.3%) and ROA (0.2%), indicating operational distress
- Operating expenses consume 59.9% of revenue despite healthy gross margins, suggesting structural inefficiencies
- Operating cash flow of only $1.2M on $116.3M revenue demonstrates poor cash conversion quality
- Net margin of 2.2% and ROE of 2.2% show weak earnings quality relative to sales growth
- Free cash flow is near breakeven, limiting internally funded reinvestment and debt reduction
- Interest coverage of 1.4x leaves little cushion if financing costs stay elevated or earnings soften
Key Metrics to Watch
- Free cash flow trajectory and return to positive territory
- Operating margin expansion and OpEx rationalization efforts
- Debt service coverage ratio and refinancing capability given interest coverage constraints
- Operating cash flow conversion rate relative to net income
- Operating margin expansion and interest coverage improvement
- Free cash flow generation relative to revenue growth
Artivion, Inc.. (AORT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.86x current ratio provides a solid financial cushion.
AORT Profit Margin, ROE & Profitability Analysis
AORT vs Healthcare Sector: How Artivion, Inc.. Compares
How Artivion, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Artivion, Inc.. Stock Overvalued? AORT Valuation Analysis 2026
Based on fundamental analysis, Artivion, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Artivion, Inc.. Balance Sheet: AORT Debt, Cash & Liquidity
AORT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Artivion, Inc..'s revenue has grown significantly by 48% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.75 indicates the company is currently unprofitable.
AORT Revenue Growth, EPS Growth & YoY Performance
AORT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $99.0M | -$505.0K | $-0.01 |
| Q3 2025 | $95.8M | -$2.3M | $-0.05 |
| Q2 2025 | $98.0M | $840.0K | $0.02 |
| Q1 2025 | $97.4M | -$505.0K | $-0.01 |
| Q3 2024 | $87.9M | -$2.3M | $-0.05 |
| Q2 2024 | $89.3M | -$2.1M | $-0.05 |
| Q1 2024 | $83.2M | $7.5M | $0.18 |
| Q3 2023 | $76.8M | -$9.8M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Artivion, Inc.. Dividends, Buybacks & Capital Allocation
AORT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Artivion, Inc.. (CIK: 0000784199)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 4, 2026 | 4 | xslF345X06/wk-form4_1780606213.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779323838.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779323726.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779323634.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779323520.xml | View → |
❓ Frequently Asked Questions about AORT
What is the AI rating for AORT?
Artivion, Inc.. (AORT) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AORT's key strengths?
Claude: Strong gross margins of 64.9% indicate product value and pricing power. Revenue growth of 13.6% YoY shows market demand in medical device sector. ChatGPT: Revenue growth of 13.6% YoY indicates strong commercial momentum. Gross margin of 64.4% suggests attractive product mix and pricing power.
What are the risks of investing in AORT?
Claude: Negative free cash flow of -$6.8M indicates company is burning cash despite top-line growth. Interest coverage ratio of 0.2x is critically low - operating income insufficient to cover debt service. ChatGPT: Net margin of 2.2% and ROE of 2.2% show weak earnings quality relative to sales growth. Free cash flow is near breakeven, limiting internally funded reinvestment and debt reduction.
What is AORT's revenue and growth?
Artivion, Inc.. reported revenue of $116.3M.
Does AORT pay dividends?
Artivion, Inc.. pays dividends, with $3.4M distributed to shareholders in the trailing twelve months.
Where can I find AORT SEC filings?
Official SEC filings for Artivion, Inc.. (CIK: 0000784199) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AORT's EPS?
Artivion, Inc.. has a diluted EPS of $0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AORT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Artivion, Inc.. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AORT stock overvalued or undervalued?
Valuation metrics for AORT: ROE of 0.3% (sector avg: 15%), net margin of 1.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AORT's AI grade for 2026?
Our dual AI analysis gives Artivion, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AORT's free cash flow?
Artivion, Inc..'s operating cash flow is $1.2M, with capital expenditures of $8.0M. FCF margin is -5.9%.
How does AORT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1.2% (avg: 12%), ROE 0.3% (avg: 15%), current ratio 3.86 (avg: 2).